Cancer research and innovation: conceptualising a persistent anomaly
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer research and innovation: conceptualising a persistent anomaly
Authors
Keywords
-
Journal
Innovation-Organization & Management
Volume -, Issue -, Pages 1-35
Publisher
Informa UK Limited
Online
2023-05-03
DOI
10.1080/14479338.2023.2204322
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Asciminib: First Approval
- (2022) Emma D. Deeks DRUGS
- Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
- (2022) Laura D. Wood et al. GASTROENTEROLOGY
- The current state of the art and future trends in RAS-targeted cancer therapies
- (2022) Salman R. Punekar et al. Nature Reviews Clinical Oncology
- Intratumoral heterogeneity in cancer progression and response to immunotherapy
- (2021) Ilio Vitale et al. NATURE MEDICINE
- Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
- (2021) Ya-Ching Hsieh et al. LEUKEMIA
- Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia
- (2021) Hiroto Inaba et al. Journal of Clinical Medicine
- Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
- (2021) Michael J. Grant et al. Nature Reviews Clinical Oncology
- Targeting Mutated KRAS Genes to Treat Solid Tumours
- (2021) Tharani Krishnan et al. Molecular Diagnosis & Therapy
- Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
- (2021) Timothée Olivier et al. JAMA Network Open
- Current issues and perspectives in PD-1 blockade cancer immunotherapy
- (2020) Kenji Chamoto et al. International Journal of Clinical Oncology
- Tumour-agnostic therapies
- (2020) Ann-Marie Looney et al. NATURE REVIEWS DRUG DISCOVERY
- Cancer Classification at the Crossroads
- (2020) Antonino Carbone Cancers
- Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response
- (2020) Daniel F. Carr et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Current methods in translational cancer research
- (2020) Michael W. Lee et al. CANCER AND METASTASIS REVIEWS
- Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
- (2020) Dongsung Kim et al. CELL
- Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
- (2020) Timothy J Voorhees et al. Cancers
- Larotrectinib: First Global Approval
- (2019) Lesley J. Scott DRUGS
- Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
- (2019) Kamal Chamoun et al. Journal of Hematology & Oncology
- Implementing Precision Medicine in Community-Based Oncology Programs: Three Models
- (2019) Laura A. Levit et al. Journal of Oncology Practice
- Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
- (2019) David T Teachey et al. LANCET ONCOLOGY
- Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer
- (2019) Cinzia Dello Russo et al. CLINICAL THERAPEUTICS
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contemporary Outcomes for Advanced‐Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database
- (2019) Guru Subramanian Guru Murthy et al. ONCOLOGIST
- Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
- (2019) Michael Orth et al. Radiation Oncology
- Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
- (2018) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Time to challenge the spurious hierarchy of systematic over narrative reviews?
- (2018) Trisha Greenhalgh et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2018) John Heymach et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic developments in pancreatic cancer: current and future perspectives
- (2018) John P. Neoptolemos et al. Nature Reviews Gastroenterology & Hepatology
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity in Lung Cancer
- (2018) Vitor Manuel Leitão de Sousa et al. PATHOBIOLOGY
- Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries
- (2018) Hongmei Zeng et al. Lancet Global Health
- Treatment of Advanced Non–Small Cell Lung Cancer in 2018
- (2018) Deborah B. Doroshow et al. JAMA Oncology
- Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
- (2017) Etienne Giroux Leprieur et al. EUROPEAN JOURNAL OF CANCER
- What is precision medicine?
- (2017) Inke R. König et al. EUROPEAN RESPIRATORY JOURNAL
- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2017) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
- (2017) Andrew M. Waters et al. Cold Spring Harbor Perspectives in Medicine
- Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
- (2016) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rescuing the Lost in Translation
- (2016) Sinje Gehr et al. CELL
- Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2016) Don S. Dizon et al. JOURNAL OF CLINICAL ONCOLOGY
- Changing R&D models in research-based pharmaceutical companies
- (2016) Alexander Schuhmacher et al. Journal of Translational Medicine
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
- (2016) Faiyaz Notta et al. NATURE
- Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non‐Small Cell Lung Cancer and the Role of Biopsy at Progression
- (2016) Mark A. Socinski et al. ONCOLOGIST
- Pancreatic Cancer from Molecular Pathways to Treatment Opinion
- (2016) Michail Karanikas et al. Journal of Cancer
- Deep molecular responses for treatment-free remission in chronic myeloid leukemia
- (2016) Stéphanie Dulucq et al. Cancer Medicine
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- New approaches for improving outcomes in breast cancer in Europe
- (2015) Angelo Di Leo et al. BREAST
- Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014
- (2015) P Savage et al. BRITISH JOURNAL OF CANCER
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
- (2015) Manuel Hidalgo et al. PANCREATOLOGY
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- A note from history: Landmarks in history of cancer, Part 6
- (2013) Steven I. Hajdu et al. CANCER
- Cancer heterogeneity—a multifaceted view
- (2013) Felipe De Sousa E Melo et al. EMBO REPORTS
- An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011
- (2013) Michael Lanthier et al. HEALTH AFFAIRS
- Management of non-small-cell lung cancer: recent developments
- (2013) Martin Reck et al. LANCET
- Acute lymphoblastic leukaemia
- (2013) Hiroto Inaba et al. LANCET
- Rethinking the war on cancer
- (2013) Douglas Hanahan LANCET
- The Incidence and Survival Rate of Population-Based Pancreatic Cancer Patients: Shanghai Cancer Registry 2004–2009
- (2013) Jianfeng Luo et al. PLoS One
- Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials
- (2012) Domenico Ciliberto et al. EUROPEAN JOURNAL OF CANCER
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Raise standards for preclinical cancer research
- (2012) C. Glenn Begley et al. NATURE
- Population Sciences, Translational Research, and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century
- (2011) M. J. Khoury et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Believe it or not: how much can we rely on published data on potential drug targets?
- (2011) Florian Prinz et al. NATURE REVIEWS DRUG DISCOVERY
- Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
- (2011) Enrico Derenzini et al. Genome Medicine
- The importance of new companies for drug discovery: origins of a decade of new drugs
- (2010) Robert Kneller NATURE REVIEWS DRUG DISCOVERY
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL
- (2009) A A Mian et al. LEUKEMIA
- Pharma positions to survive the impending patent cliff
- (2009) Mike May NATURE MEDICINE
- Lessons from 60 years of pharmaceutical innovation
- (2009) Bernard Munos NATURE REVIEWS DRUG DISCOVERY
- The Meaning of Translational Research and Why It Matters
- (2008) Steven H. Woolf JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started